Pfizer Reports Exit and Disposal Costs

TL;DR

Pfizer's filing an 8-K for exit/disposal costs - likely restructuring.

AI Summary

On May 22, 2024, Pfizer Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify any dollar amounts or specific dates for these activities, but it indicates a formal reporting of these costs.

Why It Matters

This filing signals that Pfizer is undergoing restructuring or divesting certain assets, which could impact future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Disposal activities can indicate financial strain or strategic shifts that may carry inherent risks for investors.

Key Players & Entities

• Pfizer Inc. (company) — Registrant
• May 22, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $1.5 billion — ted to deliver savings of approximately $1.5 billion by the end of 2027, some of which is ex
• $1.7 billion — rogram are expected to be approximately $1.7 billion and primarily include severance and imp

Filing Documents

• pfe-20240522.htm (8-K) — 35KB
• 0000078003-24-000113.txt ( ) — 196KB
• pfe-20240522.xsd (EX-101.SCH) — 3KB
• pfe-20240522_def.xml (EX-101.DEF) — 15KB
• pfe-20240522_lab.xml (EX-101.LAB) — 27KB
• pfe-20240522_pre.xml (EX-101.PRE) — 16KB
• pfe-20240522_htm.xml (XML) — 4KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities In the second quarter of 2024, Pfizer announced it is launching a multi-year program to reduce our cost of goods sold. This cost reduction program (the "program") will span multiple years, and is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. Given the complexity in manufacturing and longer lead times required to make changes, this program will be a multi-phased effort. The first phase of the program is focused on operational efficiencies and is expected to deliver savings of approximately $1.5 billion by the end of 2027, some of which is expected to begin being realized in 2025. The one-time costs to achieve the savings associated with the first phase of the program are expected to be approximately $1.7 billion and primarily include severance and implementation costs. These costs will be recorded primarily in 2024, with cash outlays expected in 2025 and 2026. The estimate of costs that Pfizer expects to incur for the first phase of the program, and the timing thereof, are subject to a number of assumptions and actual results may differ from current expectations. Pfizer may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the first phase of the program as well as for potential future phases. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Pfizer's anticipated operating and financial performance and a multi-year program to reduce our cost of goods sold (including anticipated costs, savings and potential benefits) that involves substantial risks and

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. Dated: May 22, 2024 By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel

View Full Filing

View this 8-K filing on SEC EDGAR